Review
[Therapeutic prospects and lymphoproliferative syndromes related to EBV]
[Article in
French]
Affiliations
- PMID: 9538413
Item in Clipboard
Review
[Therapeutic prospects and lymphoproliferative syndromes related to EBV]
[Article in
French]
Ann Med Interne (Paris).
1997.
Abstract
The B lymphoproliferative disorders are a major (10%) and severe (70% mortality) complication of immunosuppression required for HLA-mismatched bone marrow or organ transplantation. An experimental model was developed in which patients infected EBV-B cells are inoculated into scid mice and develop into tumors, allowing evaluation of treatment efficacy: monoclonal antibodies directed to membrane antigens of tumoral cells (monoclonal antibodies anti-B), monoclonal antibodies neutralizing interleukins (and especially IL6), cytotoxic T cells. Results obtained with these three different approaches are herein reported.
Similar articles
-
Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies.J Clin Invest. 1992 Sep;90(3):945-52. doi: 10.1172/JCI115971. J Clin Invest. 1992. PMID: 1326002 Free PMC article.
-
Overview of posttransplant B-cell lymphoproliferative disorders.Semin Oncol. 1999 Oct;26(5 Suppl 14):21-5. Semin Oncol. 1999. PMID: 10561014 Review.
-
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.Clin Cancer Res. 2003 May;9(5):1931-9. Clin Cancer Res. 2003. PMID: 12738752
-
Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.Haematologica. 2002 Jan;87(1):67-77. Haematologica. 2002. PMID: 11801467
-
Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.Blood Rev. 2004 Sep;18(3):193-209. doi: 10.1016/j.blre.2003.12.002. Blood Rev. 2004. PMID: 15183903 Review.
Publication types
MeSH terms
LinkOut - more resources
Research Materials